Tag: crohns disease (CD) treatment industry analysis

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Crohn’s Disease (CD) Treatment Market Size From 2025 to 2034?

The market size for treatment of Crohn’s disease (cd) has seen a consistent rise over the past years. It’s projected to leap from $11.76 billion in 2024 to $12.32 billion in 2025, boasting a compound annual growth rate (CAGR) of 4.8%. This observable growth through the historic era can be credited to an increase in cases of Crohn’s disease, a burgeoning understanding of the ailment, groundwork initiatives by the government, and lifestyle modifications.

The market size for the treatment of Crohn’s disease (CD) is predicted to experience robust growth in the upcoming years. It is projected to reach $15.01 billion in 2029, with a compound annual growth rate (CAGR) of 5.1%. This substantial increase during the forecast period can be credited to a rising demand for combination therapies, enhanced adoption of biologics, and significant investment in research and development for Crohn’s disease (CD) treatments. Within the forecast period, major trends are expected to revolve around the development of biologic drugs, inventive products, sophisticated diagnostic tools, and the adoption of biosimilars.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Which Primay Drivers Are Accelerating Growth in the Crohn’s Disease (CD) Treatment Market?

The growth of the Crohn’s disease (CD) treatment market is anticipated to be accelerated by the rising prevalence of inflammatory bowel diseases. These are a set of chronic inflammatory conditions predominantly influencing the gastrointestinal (GI) tract. Treatment of Crohn’s disease aims to alleviate symptoms, mitigate inflammation, foster remission, and improve the overall quality of life for those afflicted by chronic inflammatory bowel disease. In September 2023, the US-based United States National Library of Medicine estimated the incidence of inflammatory bowel diseases (IBD) in Canada to be about 30 per 100,000 person-years in 2023, with an expected regular increment of nearly 0.58% annually. By the year 2023, the occurrence of IBD in Canada was about 825 per 100,000, with predictions indicating a potential rise to 1.1% of the population by 2035. Consequently, the escalating incidence of inflammatory bowel diseases propels the growth of the Crohn’s disease (CD) treatment market.

Which Primary Segments of the Crohn’s Disease (CD) Treatment Market Are Driving Growth and Industry Transformations?

The crohn’s disease (cd) treatmentmarket covered in this report is segmented –

1) By Drug Type: Antibiotics; Amino Salicylates; Corticosteroids; Immunomodulators; Other Drug Types

2) By Route of Administration: Oral; Injectable

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole; Ciprofloxacin; Rifaximin

2) By Amino Salicylates: Mesalamine; Sulfasalazine

3) By Corticosteroids: Prednisone; Budesonide; Hydrocortisone

4) By Immunomodulators: Azathioprine; Mercaptopurine; Methotrexate

5) By Other Drug Types: Biologic Therapies; Janus Kinase Inhibitors; Small Molecules

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Crohn’s Disease (CD) Treatment Market?# Market?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Crohn’s Disease (CD) Treatment Industry Dynamics?

Leading firms in the Crohn’s Disease (CD) treatment market are leveraging new technologies like IBDSENSE to maintain their market position. In March 2023, The IRR Chemistry Hub, an interdisciplinary hub based in Scotland, pioneered the development of IBDSENSE. The goal of this technology is to enhance the diagnosis and monitoring of inflammatory bowel disease using non-invasive techniques, including those applied to Crohn’s disease. The approach involves the use of fluorescence-based technology to determine the enzyme activity of Granzyme B (GzmB) in the biosamples sourced from patients. The inception of this technology is projected to better the patient’s experience and widen the range of treatment options.

View the full report here:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

What Parameters Are Used to Define the Crohn’s Disease (CD) Treatment Market?

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn’s disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12902

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Crohn’s Disease (CD) Treatment Market?

The market size for Crohn’s disease (CD) treatment has exhibited robust growth in the past few years. It is projected to expand from $11.76 billion in 2024 to $12.38 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. The growth rate attested during the historical period can be traced back to an increase in the incidence of Crohn’s disease, heightened consciousness about the disease, governmental endeavors, and lifestyle changes.

What Growth Rate Is Forecasted for the Crohn’s Disease (CD) Treatment Market by 2029?

The market for Crohn’s disease (CD) treatment is projected to experience considerable expansion over the coming years, expected to reach a value of $15.06 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. The projected growth during this period can be credited to the escalating demand for combined therapies, increased use of biologics, as well as investments being directed towards the research and development of treatments for Crohn’s disease (CD). Forecasts for this period delineate a trend towards the development of biologic drugs, pioneering products, refined diagnostic tools, and the adoption of biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Which Key Companies Are Shaping the Future of the Crohn’s Disease (CD) Treatment Market?

Major companies operating in the crohn’s disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.

Which Factors Are Driving Demand in the Crohn’s Disease (CD) Treatment Industry?

The increasing incidence of inflammatory bowel diseases is anticipated to drive the expansion of the Crohn’s disease (CD) treatment market. A collection of chronic inflammatory diseases mainly impacting the gastrointestinal (GI) tract is known as inflammatory bowel disease (IBD). The benefits of Crohn’s disease (CD) treatment include symptom alleviation, inflammation reduction, remission promotion, and improved quality of life for those afflicted with the chronic condition. For instance, the United States National Library of Medicine, a U.S-based medical resource center, deduced that in Canada, the rate of IBD was calculated at 30 per 100,000 individuals per annum in 2023, speculating a steady increase of about 0.58% annually. By 2023, the prevalence of IBD in Canada was around 825 per 100,000, with predictions hinting this could escalate to 1.1% of the population by 2035. Consequently, this growing prevalence of inflammatory bowel diseases propels the growth of the Crohn’s disease (CD) treatment market.

Market Driver of Crohn’s Disease (CD) Treatment: Boost in Clinical Trials Accelerates Growth in the Market for Crohn’s Disease Treatment

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

How Is the Crohn’s Disease (CD) Treatment Market Segmented by Several Divisions?

The crohn’s disease (CD) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

What are the Emerging Market Trends Driving the Growth of the Crohn’s Disease (CD) Treatment Industry?

Leading companies in the Crohn’s disease (CD) treatment sector are adopting novel technologies like IBDSENSE to maintain their market rankings. In March 2023, IBDSENSE was fabricated by The IRR Chemistry Hub, an interdisciplinary hub located in Scotland. The technology is designed to enhance diagnostic and monitoring procedures for inflammatory bowel disease using non-invasive methods, including those for Crohn’s disease. The approach utilizes fluorescence-based technology to evaluate the enzyme activity of Granzyme B (GzmB) in patient bio-samples. This innovation aims to enhance patient experience and provide more treatment options.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Which Regions Are Driving Growth in the Crohn’s Disease (CD) Treatment Market?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12902

This Report Delivers Insight On:

1. How big is the crohn’s disease (cd) treatment market, and how is it changing globally?

2. Who are the major companies in the crohn’s disease (cd) treatment market, and how are they performing?

3. What are the key opportunities and risks in the crohn’s disease (cd) treatment market right now?

4. Which products or customer segments are growing the most in the crohn’s disease (cd) treatment market?

5. What factors are helping or slowing down the growth of the crohn’s disease (cd) treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the crohn’s disease (cd) treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Crohn’s Disease (CD) Treatment Market Expected to Grow Between 2025 And 2029?

The market size for Crohn’s disease (CD) treatment has seen significant growth in the recent past. It is predicted to expand from $11.76 billion in 2024 to $12.38 billion in 2025, projecting a compound annual growth rate (CAGR) of 5.3%. The previous growth trends have been the result of increasing cases of Crohn’s disease, heightened disease awareness, initiatives by the government, and lifestyle changes.

Significant expansion is anticipated in the Crohn’s disease (CD) treatment market size within the forthcoming years, with a projected growth to $15.06 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. This predicted growth during the forecast period can be associated with the rising demand for combination therapies, the increasing use of biologics, and financial investments in the research and development of Crohn’s disease (cd) treatments. The period’s major trends include the development of biologic drugs, the introduction of innovative products, the advancement of diagnostic tools, and the uptake of biosimilars.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Which Primay Drivers Are Accelerating Growth in the Crohn’s Disease (CD) Treatment Market?

The growth of the Crohn’s disease (CD) treatment market is anticipated to be propelled by the escalating prevalence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) is a collection of ongoing inflammatory conditions, primarily targeting the gastrointestinal (GI) tract. The treatment of Crohn’s disease (CD) provides symptom relief, reduces inflammation, encourages remission, and enhances the overall life quality for individuals afflicted with chronic inflammatory bowel disease. For instance, in September 2023, data from the United States National Library of Medicine, a medical library based in the US, revealed that in Canada, the rate of inflammatory bowel diseases (IBD) in 2023 was estimated to be around 30 per 100,000 person years, with future projections hinting at a steady growth rate of approximately 0.58% per annum. By 2023, the incidence of IBD in Canada had reached around 825 per 100,000, with predictions suggesting this might escalate to 1.1% of the population by 2035. Accordingly, the escalating prevalence of inflammatory bowel diseases is driving the Crohn’s disease (CD) treatment market forward. The Crohn’s Disease (CD) Treatment Market growth is driven by the increment in clinical trials. The rising number of clinical trials is expected to foster the development of the Crohn’s disease treatment market. They are crucial for verifying the safety and effectiveness of these innovative therapies, and their success paves the way for regulatory approvals and the emergence of new treatment alternatives for CD patients. The pursuit for more potent Crohn’s disease treatments stimulates clinical trials, with both patients and healthcare providers yearning for improved outcomes and reduced side effects, spurring research and development initiatives. For instance, in September 2023, the University of California, a public land-grant research university based in the US, indicated that there are currently 17 ongoing clinical trials at UCSF specifically focusing on the use of vedolizumab and oral ozanimod, with goals to evaluate the long-term effectiveness of mirikizumab for pediatric patients suffering from Crohn’s disease or ulcerative colitis. Consequently, the surge in the number of clinical trials is expected to stimulate the growth of the Crohn’s disease treatment market in the future.

Which Primary Segments of the Crohn’s Disease (CD) Treatment Market Are Driving Growth and Industry Transformations?

The crohn’s disease (CD) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

Which Regions Are Key Players in the Growth of the Crohn’s Disease (CD) Treatment Market?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Crohn’s Disease (CD) Treatment Industry Dynamics?

Leading enterprises in the Crohn’s disease (CD) treatment sector are integrating fresh technologies like IBDSENSE to maintain their market standing. For example, in March 2023, the Scotland-based interdisciplinary hub, The IRR Chemistry Hub, crafted IBDSENSE. The aim of this technology is to enhance the diagnosis and monitoring of inflammatory bowel disease, including Crohn’s disease, through non-invasive techniques. This project leverages fluorescence-based technology to gauge the enzyme activity of Granzyme B (GzmB) in patient biosamples. The goal of this technology is to refine the patient’s experience and their treatment options.

View the full report here:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

What Parameters Are Used to Define the Crohn’s Disease (CD) Treatment Market?

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn’s disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12902

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theCrohn’s Disease (CD) Treatment Market?

The escalating occurrence of inflammatory bowel diseases is predicted to be a factor contributing to the growth of the Crohn’s disease (CD) treatment market. Inflammatory bowel disease (IBD) consists of a range of chronic inflammatory disorders predominantly impacting the gastrointestinal (GI) tract. Treatments for Crohn’s disease (CD) offer symptom relief, reduce inflammation, push the disease into remission, and improve the overall quality of life for those with the chronic condition. For example, the United States National Library of Medicine mentioned in September 2023 that IBD incidence in Canada was estimated to be 30 out of every 100,000 person-years in 2023, projecting a mild yearly rise of approximately 0.58%. As of 2023, the IBD prevalence in Canada had reached around 825 per 100,000, with predictions indicating this could soar to 1.1% of the population by 2035. As a result, the rising occurrence of IBD is propelling the Crohn’s disease (CD) treatment market. Elevated clinical trial numbers are expected to boost the Crohn’s disease treatment market. Clinical trials are necessary to ascertain the safety and effectiveness of new therapies, with successful trials potentially leading to regulatory approvals and subsequent introduction of novel treatments for CD. The need for more effective treatments for Crohn’s disease is driving clinical trials in response to patients and healthcare providers’ fervent desire for improved outcomes with minimal side effects, thereby spurring research and development initiatives. For example, the University of California stated in September 2023 that there are currently 17 ongoing clinical trials at UCSF focusing on the use of vedolizumab and oral ozanimod. These trials are aimed at evaluating the long-term effectiveness of mirikizumab in pediatric patients suffering from Crohn’s disease or ulcerative colitis. Hence, increased clinical trial activity is anticipated to stimulate the Crohn’s disease treatment market’s expansion.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

How Has the Crohn’s Disease (CD) Treatment Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

There has been a significant growth in the market size for the treatment of Crohn’s Disease (CD) in the last few years. This market is expected to increase from $11.76 billion in 2024 to $12.38 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.3%. The growth experienced in the previous years can be linked to the increasing cases of Crohn’s disease, heightened awareness about the illness, initiatives by the government and changing lifestyle trends.

Expectations are high for the Crohn’s disease (CD) treatment market, with predictions of a robust growth trajectory in the coming years. The market size is anticipated to reach $15.06 billion in 2029, expanding at a compound annual growth rate (CAGR) of 5.0%. Factors such as a rising need for combination treatments, broader acceptance of biologics, and increased investment in CD research and development are contributing to this forecasted growth. Key market trends to watch include the development of biological drugs, groundbreaking products, cutting-edge diagnostic tools, and a wider embrace of biosimilars.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12902

What Are the Latest Innovations Influencing theCrohn’s Disease (CD) Treatment Market?

Key players in the treatment market for Crohn’s disease (CD) are integrating innovative technologies like IBDSENSE to maintain their market dominance. As an example, the IRR Chemistry Hub, headquartered in Scotland, rolled out IBDSENSE in March 2023. The core intent of this technology is to enhance the diagnosis and oversight of inflammatory bowel disease with non-disruptive methods, Crohn’s disease included. The project relies on a fluorescence-based technology to assess the enzymatic activity of Granzyme B (GzmB) in the biosamples of patients. Through this technology, the goal is to refine the patient experience and expand treatment options.

Who Are the Major Industry Players Accelerating Growth in theCrohn’s Disease (CD) Treatment Market?

Major companies operating in the crohn’s disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Which Primary Segments of the Crohn’s Disease (CD) Treatment Market Are Driving Growth and Industry Transformations?

The crohn’s disease (CD) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theCrohn’s Disease (CD) Treatment Market?# Market?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Crohn’s Disease (CD) Treatment Market 2025, By The Business Research Company:

Gastric Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Volvulus Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Rapidly is the Crohn’s Disease (CD) Treatment Market Expected to Expand Between 2025 and 2034 Based on Current Trends?

The market size for treatment of Crohn’s Disease (CD) has seen significant growth in the past few years. The size is expected to escalate from $11.76 billion in 2024 to $12.38 billion in 2025, exhibiting a 5.3% compound annual growth rate (CAGR). The remarkable growth observed in the historical period can be credited to the increasing occurrences of Crohn’s disease, heightened consciousness about the condition, government efforts, and lifestyle changes.

In the coming years, the market for Crohn’s disease (CD) treatment is projected to experience impressive growth, to reach $15.06 billion in 2029, with a compound annual growth rate (CAGR) of 5.0%. This growth during the forecast period can be attributed to the rising demand for combination therapies, the growing use of biologics, and increased investment in research and development for Crohn’s disease treatments. Some of the major trends expected during this period include the development of biologic drugs, the creation of innovative products, the use of advanced diagnostic tools, and the adoption of biosimilars.

Which Primary Drivers Are Supporting the Continued Expansion of the crohn’s disease (cd) treatment Market?

The Crohn’s disease (CD) treatment market is set to witness accelerated growth due to the escalating prevalence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) is a collection of chronic inflammatory conditions primarily impacting the gastrointestinal (GI) tract. The treatment for Crohn’s disease (CD) provides symptom relief, inflammation reduction, promotion of remission, and enhancement of overall quality of life for those affected by chronic inflammatory bowel disease. For instance, in September 2023, the United States National Library of Medicine, a medical library in the US, cited that Canada’s incidence of inflammatory bowel diseases (IBD) was estimated to be at 30 per 100,000 person years in 2023, with a projected steady rise of about 0.58% annually. In 2023, Canada’s IBD prevalence hit around 825 per 100,000, with predictions indicating a potential rise to 1.1% of the population by 2035. As a result, the rising incidence of inflammatory bowel diseases is a key driver of the Crohn’s disease (CD) treatment market.

Driving the Crohn’s Disease (CD) Treatment Market: Increased Clinical Trials Contribute to its Expansion

 

Explore Comprehensive Insights Into The Global Crohn’s Disease (CD) Treatment Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Which Key Players Are Shaping the Future of the Crohn’s Disease (CD) Treatment Market?

Major companies operating in the crohn’s disease (cd) treatment market are:

• Pfizer Inc._x000D_

• Johnson and Johnson Ltd._x000D_

• Merck and Co. Inc._x000D_

• AbbVie Inc._x000D_

• Novartis AG_x000D_

How Are the Latest Trends Influencing the Growth of the Crohn’s Disease (CD) Treatment Market?

Key players in the Crohn’s disease (CD) treatment market are innovating by launching new technologies like IBDSENSE to maintain their market stance. For example, The IRR Chemistry Hub, an interdisciplinary hub based in Scotland, rolled out IBDSENSE in March 2023. This technology focuses on enhancing the diagnosis and monitoring of inflammatory bowel diseases using non-invasive methodologies, amongst which Crohn’s disease is included. The initiative leverages fluorescence-based technology for the measurement of Granzyme B (GzmB) enzyme activity in patient biosamples. The objective of this technology is to elevate patient experiences and diversify treatment options.

Secure Your Global Crohn’s Disease (CD) Treatment Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

What Are the Core Segments of the Crohn’s Disease (CD) Treatment Market, and How Do They Contribute to Growth?

The crohn’s disease (CD) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

What Regions Are At the Forefront of Crohn’s Disease (CD) Treatment Market Expansion?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Crohn’s Disease (CD) Treatment Market Classified and Defined in Market Analysis?

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn’s disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

Browse Through More Similar Reports By The Business Research Company:

Gastric Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Volvulus Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: